Andrew K Cheng
Overview
Explore the profile of Andrew K Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
2464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gallant J, Koenig E, Andrade-Villanueva J, Chetchotisakd P, DeJesus E, Antunes F, et al.
J Infect Dis
. 2013 Mar;
208(1):32-9.
PMID: 23532097
Background: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity in vitro. Methods: An international, randomized, double-blind, double-dummy, active-controlled trial was conducted to evaluate the efficacy and safety of COBI...
12.
Zolopa A, Sax P, DeJesus E, Mills A, Cohen C, Wohl D, et al.
J Acquir Immune Defic Syndr
. 2013 Feb;
63(1):96-100.
PMID: 23392460
We report week 96 results from a phase 3 trial of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF, n = 348) vs efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF, n = 352). At week 48, EVG/COBI/FTC/TDF...
13.
Rockstroh J, DeJesus E, Henry K, Molina J, Gathe J, Ramanathan S, et al.
J Acquir Immune Defic Syndr
. 2013 Jan;
62(5):483-6.
PMID: 23337366
This ongoing, randomized, double-blind, active-controlled phase 3 international trial demonstrated the noninferior efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) compared with atazanavir boosted by ritonavir (ATV/RTV) plus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) at...
14.
Sax P, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al.
Lancet
. 2012 Jul;
379(9835):2439-2448.
PMID: 22748591
Background: The integrase inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) in a single tablet given once daily. We...
15.
DeJesus E, Rockstroh J, Henry K, Molina J, Gathe J, Ramanathan S, et al.
Lancet
. 2012 Jul;
379(9835):2429-2438.
PMID: 22748590
Background: The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) into a once-daily, single tablet....
16.
Negra M, Carvalho A, Zilda de Aquino M, da Silva M, Pinto J, White K, et al.
Pediatr Infect Dis J
. 2012 Feb;
31(5):469-73.
PMID: 22301477
Background: There are few data on the safety and antiviral activity of tenofovir disoproxil fumarate (TDF) in HIV-1 infected adolescents. Methods: A randomized, double-blinded, placebo-controlled study was conducted. Ninety adolescents...
17.
Molina J, LaMarca A, Andrade-Villanueva J, Clotet B, Clumeck N, Liu Y, et al.
Lancet Infect Dis
. 2011 Oct;
12(1):27-35.
PMID: 22015077
Background: Elvitegravir is a once daily inhibitor of HIV-1 integrase boosted by ritonavir. We aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 integrase inhibitor, in...
18.
Zolopa A, Berger D, Lampiris H, Zhong L, Chuck S, Enejosa J, et al.
J Infect Dis
. 2010 Feb;
201(6):814-22.
PMID: 20146631
Background: This phase 2, randomized, active-controlled, 48-week study assessed the noninferiority of the human immunodeficiency virus (HIV) integrase inhibitor elvitegravir to comparator ritonavir-boosted protease inhibitor (CPI/r) in treatment-experienced subjects. Methods:...
19.
Margot N, Enejosa J, Cheng A, Miller M, McColl D
J Acquir Immune Defic Syndr
. 2009 Aug;
52(2):209-21.
PMID: 19644384
Study 934 was an open-label, randomized Phase III study of emtricitabine + tenofovir DF + efavirenz (FTC + TDF + EFV) compared with lamivudine + zidovudine + efavirenz (3TC +...
20.
Gallant J, Winston J, DeJesus E, Pozniak A, Chen S, Cheng A, et al.
AIDS
. 2008 Oct;
22(16):2155-63.
PMID: 18832879
Background: Cases of renal dysfunction in patients receiving tenofovir disoproxil fumarate (TDF) have been reported. We analyzed the renal safety of TDF compared with thymidine analogue-containing (control) regimens through 144...